-
Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying
Friday, June 29, 2018 - 11:10am | 435Read More...Acceleron Pharma Inc (NASDAQ: XLRN), a clinical-stage biopharmaceutical focused on the treatment of serious and rare diseases, saw its stock soar after reporting encouraging Phase 3 data. But investors who are aggressive on the stock may want to reconsider, according to Goldman Sachs. The Analyst...
-
Analysts Confident In Acceleron Pharma's Drug Trial Outcomes
Thursday, June 23, 2016 - 1:30pm | 374Read More...Barclays reiterated its Overweight rating on Acceleron Pharma Inc (NASDAQ: XLRN) after a meeting with management reinforced key elements of the firm's thesis on the company, particularly regarding the drug Luspatercept. Luspatercept And Acceleron's Recent Performance Acceleron's lead...
-
Barclays Raises Acceleron Price Target On Positive Luspatercept Data
Monday, June 13, 2016 - 10:10am | 337Read More...Barclays has raised the price target of Acceleron Pharma Inc (NASDAQ: XLRN) shares to $42 (18.5 percent upside) from $40, based on a recent data showing luspatercept's durability of response in MDS. Myelodysplastic Syndromes (MDS) is a condition where the bone marrow does not produce enough healthy...
-
Janney: Time To Buy Acceleron
Monday, February 29, 2016 - 1:52pm | 315Read More...On Monday, Janney issued a company note on Acceleron Pharma Inc (NASDAQ: XLRN) after the company announced positive Phase III trial results of their drug that treats metastatic renal cell carcinoma (mRCC). Analysts at Janney upgraded Acceleron from Neutral to Buy, while lowering their price target...
-
The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron
Thursday, January 21, 2016 - 8:35am | 286Read More...Acceleron Pharma Inc (NASDAQ: XLRN) shares have plunged 23 percent since December 21. Credit Suisse’s Kennen MacKay initiated coverage of the company with an Outperform rating and a price target of $50. The Street is less bullish about luspatercept due to competition from gene...
